Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CHF)
Sales 2016 51 094 M
EBIT 2016 17 667 M
Net income 2016 11 298 M
Debt 2016 10 921 M
Yield 2016 3,85%
Sales 2017 53 664 M
EBIT 2017 18 788 M
Net income 2017 12 532 M
Debt 2017 5 872 M
Yield 2017 4,06%
P/E ratio 2016 17,03
P/E ratio 2017 15,32
EV / Sales2016 3,98x
EV / Sales2017 3,69x
Capitalization 192 340 M
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
12/07Presentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
03:49p ROCHE : FDA Approves Genentech's Avastin (Bevacizumab) Plus Chemotherapy for a S..
12:25p ROCHE : New cancer drug shows promise in helping patients with blood cancer
09:33a FOUNDATION MEDICINE INC. : Receives Average Recommendation of Hold from Analysts
06:11a ROCHE : Approval of multi-product funding proposal with Roche
02:34a ROCHE : Ventana Medical lays off 84 workers in Oro Valley
12/06 ROCHE : FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy ..
12/06 ROCHE : Federal Contracts Awarded to Companies in Indiana (Dec. 6)
12/06 ROCHE : MILITARY $5.36 Million Federal Contract Awarded to Roche Diagnostics
12/05 ROCHE : Major PHARMAC funding package agreed with Roche
12/05 ROCHE : Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymph..
More news
Sector news : Pharmaceuticals - NEC
07:16pDJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug
07:15pDJABBOTT LABORATORIES : Seeks to Terminate Alere Deal
07:05p MYLAN : EpiPen maker Mylan to restructure and cut its workforce
05:34pDJMARKET SNAPSHOT : Dow, S&P 500 Set Intraday Records, But Health-care Slumps On T..
04:19pDJMARKET SNAPSHOT : Dow, S&P 500 On Track For Records, But Health-care Slumps On T..
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 286  CHF
Spread / Average Target 29%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.190 397
JOHNSON & JOHNSON9.09%304 863
PFIZER INC.-2.23%191 517
ROCHE HOLDING LTD.-19.65%190 397
NOVARTIS AG-20.79%180 387
MERCK & CO., INC.14.12%166 200
More Results